vimarsana.com
Home
Live Updates
Study Confirming Overwhelming Reduction in Bleeding of the Dual-Acting Factor XI/XIa Inhibitor Abelacimab as Compared to Rivaroxaban Selected as Late-Breaker Oral Presentation at the American Heart Association Scientific Sessions : vimarsana.com
Study Confirming Overwhelming Reduction in Bleeding of the Dual-Acting Factor XI/XIa Inhibitor Abelacimab as Compared to Rivaroxaban Selected as Late-Breaker Oral Presentation at the American Heart Association Scientific Sessions
Study participants may transition from the rivaroxaban arm to abelacimab in an extension study
Related Keywords
United States ,
Philadelphia ,
Pennsylvania ,
American ,
John Glasspool ,
Study Group ,
Data Monitoring Committee ,
Broad Institute ,
Drug Administration ,
American Heart Association Scientific Sessions ,
Blackstone Life Sciences ,
Harvard Medical School ,
Anthos Therapeutics Inc ,
Pennsylvania Convention Center ,
Anthos Therapeutics ,
Late Breaking ,
Principal Investigator Christian ,
General Cardiology ,
Senior Investigator ,
Associate Member ,
Associate Professor ,
Harvard Medical ,
Breaker Presentation Details ,
Novel Factor ,
Atrial Fibrillation ,
Primary Results ,
Late Breaking Science ,
Shocking Decisions ,
Fast Track Designation ,
vimarsana.com © 2020. All Rights Reserved.